Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Enzyme Inhib Med Chem ; 38(1): 2212326, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37190931

ABSTRACT

Class II histone deacetylases (HDACs) are considered as potential targets to treat Alzheimer's disease (AD). Previously, C-3 substituted phenothiazine-containing compounds with class II HDAC-inhibiting activities was found to promote neurite outgrowth. This study replaced phenothiazine moiety with phenoxazine that contains many C-3 and C-4 substituents. Some resulting compounds bearing the C-4 substituent on a phenoxazine ring displayed potent class II HDAC inhibitory activities. Structure-activity relationship (SAR) of these compounds that inhibited HDAC isoenzymes was disclosed. Molecular modelling analysis demonstrates that the potent activities of C-4 substituted compounds probably arise from π-π stacked interactions between these compounds and class IIa HDAC enzymes. One of these, compound 7d exhibited the most potent class II HDAC inhibition (IC50= 3-870 nM). Notably, it protected neuron cells from H2O2-induced neuron damage at sub-µM concentrations, but with no significant cytotoxicity. These findings show that compound 7d is a lead compound for further development of anti-neurodegenerative agents.


Subject(s)
Antineoplastic Agents , Hydroxamic Acids , Hydroxamic Acids/pharmacology , Histone Deacetylase Inhibitors/pharmacology , Hydrogen Peroxide/pharmacology , Structure-Activity Relationship , Histone Deacetylases/metabolism , Antineoplastic Agents/pharmacology , Histone Deacetylase 1/pharmacology , Cell Proliferation
SELECTION OF CITATIONS
SEARCH DETAIL
...